Skip to main content

Table 2 Impact of pre-existing cardiovascular diseases on adequate glycemic control

From: Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study

Logistic regressions on percentage of patients with HbA 1c < 6.5%
Variable Odds Ratio 95% confidence intervals P-value
With CVD vs. without CVD 0.62 0.46, 0.82 0.001
Time indicators    
   <1 year from index 6.21 3.61, 10.70 <0.001
   1-2 years from index 6.39 3.72, 10.98 <0.001
   2-3 years from index 6.69 3.81, 11.75 <0.001
   3-4 years from index 7.66 4.24, 13.87 <0.001
   >= 4 years from index 5.62 3.02, 10.46 <0.001
Variable Odds Ratio 95% confidence intervals P-value
With CVD vs. without CVD 0.62 0.46, 0.82 0.001
Study period vs. baseline 6.47 3.71, 11.29 <0.001
Years after the index 1.00 0.92, 1.10 0.96
Linear regressions on HbA 1c (%)
Variable Coefficient 95% confidence intervals P-value
With CVD vs. without CVD 0.02 -0.10, 0.14 0.75
Time indicators    
   <1 year from index -0.80 -0.97, -0.62 <0.001
   1-2 years from index -0.78 -0.96, -0.60 <0.001
   2-3 years from index -0.76 -0.96, -0.57 <0.001
   3-4 years from index -0.88 -1.07, -0.68 <0.001
   >= 4 years from index -0.84 -1.07, -0.60 <0.001
Variable Coefficient 95% confidence intervals P-value
With CVD vs. without CVD 0.02 -0.10, 0.14 0.75
Study period vs. baseline -0.78 -0.97, -0.59 <0.001
Years after the index -0.01 -0.05, 0.03 0.65
  1. Note: CVD: cardiovascular diseases. Other controlled covariates in the regression analyses: concurrent treatment of the HbA1c measurement (metformin+SU combination therapy, metformin+glitazones combination therapy, SU monotherapy, glitazones monotherapy, metformin monotherapy, any therapies with insulin), index SU vs. glitazones, age, gender, Caucasian, duration of diabetes, never used alcohol, physical activity, country, BMI, physician specialty.